Provided by Tiger Fintech (Singapore) Pte. Ltd.

AINOS Inc.

0.5211
+0.04118.56%
Post-market: 0.4868-0.0343-6.58%18:48 EDT
Volume:75.33K
Turnover:37.08K
Market Cap:8.04M
PE:-0.33
High:0.5227
Open:0.4849
Low:0.4680
Close:0.4800
Loading ...

Ainos Receives Taiwan Hospital's Approval for Veldona Trial in Sjogren's Syndrome

MT Newswires Live
·
11 Nov 2024

Ainos announces IRB approval for Sjogren’s Syndrome clinical study

TIPRANKS
·
11 Nov 2024

Ainos Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.73 loss in 3Q 2023)

Simply Wall St.
·
09 Nov 2024

Ainos files complaints over concerns about unsual trading activity

TIPRANKS
·
08 Nov 2024

Ainos - Filed Complaints With Nasdaq Marketwatch and U.S. SEC Due to Concerns About UnUsUaL Trading Activity in Its Common Stock

THOMSON REUTERS
·
08 Nov 2024

Ainos Inc - Suspects That These Trading Activities May Involve Regulatory Violations

THOMSON REUTERS
·
08 Nov 2024

Ainos Inc - Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities

THOMSON REUTERS
·
08 Nov 2024

Ainos Q3 Net Loss $3,699,317

Benzinga
·
07 Nov 2024

Ainos secures exclusive licensing rights for 28 patent assets

TIPRANKS
·
28 Oct 2024

BRIEF-Ainos Inc Receives IRB Approval From National Taiwan University Hospital For Hiv-Oral Warts Clinical Trial

Reuters
·
25 Sep 2024

Ainos Inc: Receives Irb Approval From National Taiwan University Hospital for Hiv-Oral Warts Clinical Trial

THOMSON REUTERS
·
25 Sep 2024

Ainos Inc: Next Step Will Be Receiving Approval From Taiwan Food and Drug Administration (Tfda)

THOMSON REUTERS
·
25 Sep 2024

BRIEF-Ainos Announces Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome

Reuters
·
23 Sep 2024

Ainos Inc: Aims to Complete All Regulatory Approvals for Study in Q4 2024

THOMSON REUTERS
·
23 Sep 2024

Ainos Inc: Plan to Initiate Taiwan Clinical Study of Veldona for Treating SjÖGren's Syndrome, a Rare Disease With Limited Treatment Options

THOMSON REUTERS
·
23 Sep 2024